Carisma Therapeutics, Inc.
CARM
Rank in Stocks
#34659
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing... Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Share Price
$0.0002
Last synced: 2026-11-09
Market Cap
$8.37K
Change (1 day)
0.00%
Change (1 year)
-99.58%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Carisma Therapeutics, Inc. (CARM)
Category
Healthcare
Operating Margin for Carisma Therapeutics, Inc. (CARM)
Operating Margin as of November 2026 TTM: 84.06%
According to Carisma Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 84.06%. At the end of 2024 the company had an operating margin of -316.72%.
Operating Margin history for Carisma Therapeutics, Inc. from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 84.06% | -126.54% |
| 2024 | -316.72% | -46.75% |
| 2023 | -594.75% | 4.14% |
| 2022 | -571.10% | 438.32% |
| 2021 | -106.09% | -57.99% |
| 2020 | -252.56% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | -100.00% |
| 2017 | -4,702.35% | -22,960.23% |
| 2016 | 20.57% | -100.58% |
| 2015 | -3,555.15% | 142.15% |
| 2014 | -1,468.17% | 17.81% |
| 2013 | -1,246.25% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -99.54% |
US
|
|
| -149.01% | -101.77% |
US
|
|
| 25.57% | -99.70% |
AU
|
|
| 31.23% | -99.63% |
BE
|
|
| 29.35% | -99.65% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Carisma Therapeutics, Inc.'s operating margin
What is Carisma Therapeutics, Inc.'s operating margin?
Carisma Therapeutics, Inc.'s operating margin is 84.06%, as of Nov 2026.
What was Carisma Therapeutics, Inc.'s operating margin in 2024?
In 2024, Carisma Therapeutics, Inc.'s operating margin was -316.72%, compared with -594.75% in 2023.
How has Carisma Therapeutics, Inc.'s operating margin changed since 2019?
From 2019 to 2024, Carisma Therapeutics, Inc.'s operating margin was highest in 2019 (0.00%) and lowest in 2023 (-594.75%).
How does Carisma Therapeutics, Inc.'s operating margin compare with similar companies?
Carisma Therapeutics, Inc.'s operating margin (84.06%) is higher than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.